The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777364. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

OUR VISION

Robust data and scientific rigor determine the pace of knowledge gain and the time needed to make new drug treatments available to patients.

We believe that there is a need for simple, sustainable solutions that facilitate improvements in data quality, without impacting the innovation and freedom of basic research in academia or in the pharmaceutical industry.

Our aim is to enable a smoother, faster and safer transition from preclinical to clinical testing and drug approval by establishing common guidelines that will strengthen the robustness, rigor and validity of research data.

The project pools team leaders and resources from academia and industry in the fields of neuroscience and drug safety, but will provide applicability beyond these research areas.

OUR OBJECTIVES

With a primary focus on Alzheimer's disease and psychosis, the EQIPD consortium will

- define those variables within industrial study design and data analysis that influence the outcome of preclinical neuroscience research and drug safety trials the most
- establish whether these are the same variables that affect the outcome of studies conducted in academia

VALIDITY OF RESEARCH DATA: A KEY DRIVER FOR DECISION MAKING IN MEDICAL SCIENCES

- define the components that will make up the EQIPD quality management system
- formulate consensus quality management recommendations for previously non-regulated research and development
- validate the feasibility of the quality management system in actual studies
- deliver an online educational platform providing certified education and training in the principles and application of quality management and rigor

WHY OUR RESEARCH MATTERS

So far, there are no comprehensive, generally agreed-upon, and universally applicable guiding principles or criteria governing rigor in the design, conduct and analysis of preclinical neuroscience studies and drug-safety research. In comparison, the reporting of such research is already fairly standardized.

As a result, the development of new drugs and novel medical treatments has slowed down dramatically over the past 10 years, with the number of drugs in development having decreased by 70 % since 2005. This is mostly due to the complexity of drug development and drug-safety trials, leading to a significant failure rate.

The EQIPD project aims to reverse this trend.

Our consortium that unites more than 20 research groups from industry and academia within 9 separate work packages will develop strategies to ensure that preclinical research and early drug development studies proceed along structured guidelines.

- ABBVIE INC.
  North Chicago, Illinois, USA
- ARLENDA S.A.
  Mont-Saint-Guibert, Belgium
- BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  Ingelheim, Germany
- CHARITÉ-UNIVERSITÄTSMEDIZIN BERLIN
  Berlin, Germany
- CONCENTRIS RESEARCH MANAGEMENT GMBH
  Fürstenfeldbruck, Germany
- EBERHARD KARLS UNIVERSITÄT TÜBINGEN
  Tübingen, Germany
- F. HOFFMANN-LA ROCHE AG
  Basel, Switzerland
- IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
  London, United Kingdom
- INSTITUT DE RECHERCHES SERVIER
  Croissy-sur-Seine, France
- JANSSEN PHARMACEUTICA N.V.
  Beerse, Belgium
- LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN
  Munich, Germany
- NOLDUS INFORMATION TECHNOLOGY BV
  Wageningen, The Netherlands
- NOVARTIS PHARMA AG
  Basel, Switzerland
- ORION CORPORATION
  Espoo, Finland
- PAASP GMBH
  Heidelberg, Germany
- PFIZER LTD.
  Tadworth, United Kingdom
- PORSOLT SAS
  Le Genest-Saint-Isle, France
- PSYCHOGENICS INC.
  Paramus, New York, USA
- RADBOUD UNIVERSITY MEDICAL CENTER
  Nijmegen, The Netherlands
- SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
  Chilly-Mazarin, France
- SCIENCE EXCHANGE, INC.
  Palo Alto, California, USA
- STICHTING BURO ECNP
  Utrecht, The Netherlands
- SYNAPTOLOGICS B.V.
  Amsterdam, The Netherlands
- UCB BIOPHARMA SPRL
  Brussels, Belgium
- UNIVERSITÄT BERN
  Bern, Switzerland
- UNIVERSITÄTSMEDIZIN DER JOHANNES-GUTENBERG-UNIVERSITÄT MAINZ
  Mainz, Germany
- UNIVERSITY OF ABERDEEN
  Aberdeen, United Kingdom
- UNIVERSITY OF EDINBURGH
  Edinburgh, United Kingdom
- UNIVERSITY OF GRONINGEN (RIJKSUNIVERSITEIT)
  Groningen, The Netherlands

MEMBERS

EQIPD is an international research project that brings together 29 transdisciplinary institutions from 8 different countries.

THE EQIPD PROJECT: BASIC FACTS AND FIGURES

FULL PROJECT TITLE	European Quality In Preclinical Data
START DATE	01 Oct 2017
DURATION TIME	36 months
PARTICIPANTS	29 institutions from 8 different countries
IMI FUNDING	4,5 million € (4,495,523.00 €)
PROJECT WEBSITE	www.eqipd.org

Follow EQIPD on:

www.twitter.com/ECNPtweets

www.linkedin.com/groups/12074241/profile

www.facebook.com/EQIPD

CONTACT

PROJECT COORDINATOR	**Prof. Dr. Malcolm Macleod,** University of Edinburgh → malcolm.macleod@ed.ac.uk
PROJECT LEADER	**Dr. Thomas Steckler,** Janssen Pharmaceutica N.V. → tsteckle@its.jnj.com
PROJECT MANAGEMENT	**Dr. Sara Stöber,** concentris research management GmbH → sara.stoeber@concentris.de **Kathleen Wuyts,** Janssen Pharmaceutica N.V. → kwuyts6@its.jnj.com